Current Price{{movement}} ${{quote.Last.toFixed(3) == 0.000 ? quote['CF CLOSE'].toFixed(3) : quote.Last.toFixed(3)}} (20 minute delay)
Today's Change ${{quote['Net Change'].toFixed(3)}} ({{quote['% Change']}}%) Market is currently: {{(quote['Price Qualifier Code'] == 'OPN' || quote['Price Qualifier Code'] == 'SUS') ? "OPEN" : "CLOSED"}}
Open {{quote['Opening Price'].toFixed(3)}} Prev Close {{quote['Historic Close'].toFixed(3)}}
Today's High {{quote["Today's High"].toFixed(3)}} Today's Low {{quote["Today's Low"].toFixed(3)}}
Broker Consensus

No Data Available

  • Sell
  • Reduce
  • Hold
  • Buy
  • Strong Buy

Tissue Therapies Limited (TIS)
is a publicly listed company on the Australian Securities Exchange (ASX).


{{businessSummary}}

General Overview

About Tissue Therapies Limited

TIS

Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns.

Tissue Therapies Limited is commercialising VitroGro® ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology.

The company is also developing treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate.

Tissue Therapies Limited's shares are traded on the Australian, Berlin and Frankfurt stock exchanges.

Tissue Therapies is currently focused on launching VitroGro® ECM in Europe and preparing the way for entering the USA and rest of world markets. In addition, the company is driven to expand its product line by exploring additional indications (use) of VitroGro® ECM while developing new intellectual property and new products.

Growth Strategy

They see opportunities to have significant impact in wound care markets in Asia, Australia, Canada, Europe, New Zealand, the United States and other markets experiencing the economic burden of wound care. They are also continuing to work with their research and development partners to create more effective, complimentary products for wound care and tissue repair.

Commercialisation Strategy

Tissue Therapies Limited:

  • Has exceptional clinical trial data and entered into a commercial partnership with Quintiles for sales of VitroGro® ECM in Europe.
  • Is proceeding with regulatory approvals and reimbursement approvals in the Company's name.
  • Has successfully completed commercial scale GMP manufacturing and has realised inventory in readiness for sale.
  • Is proceeding with development of other commercial applications for VitroGro® and other technologies for the treatment of psoriasis, scar prevention and treatment and potential treatments for various cancers including those of the breast, colon and prostate.

Products

VitroGro® ECM

TISVitroGro® ECM is a sterile, acellular biomimetic scaffold for the treatment of hard-to-heal wounds, primarily venous leg ulcers. VitroGro® ECM replaces degraded wound matrix. VitroGro® ECM binds to a prepared wound bed and provides a scaffold for cell attachment, which is a primary requirement for subsequent cell functions critical for healing, such as, cell proliferation and migration. VitroGro® ECM improves wound closure and reduces pain thereby improving wound care.

Chronic, hard to heal wounds are characterised by prolonged inflammation that degrades ECM components and senescent skin cells with a reduced capacity to maintain the balance of the ECM.

VitroGro® ECM replaces the degraded ECM in a chronic wound bed by forming a physical surface matrix by adsorption to damaged ECM in the wound bed. VitroGro® ECM is designed to be sticky to assist with adherence to the wound bed. Adhesion of skin cells in the wound to a functional ECM is a primary requirement for subsequent cell functions critical to wound healing, such as proliferation, migration, cell survival, and synthesis of new ECM. If cell attachment does not occur, these functions are not possible. The scaffold provided by VitroGro® ECM is a structure for cellular attachment and proliferation, leading to regeneration of the body's natural ECM. Newly attached cells in the wound bed subsequently produce new native ECM, which in turn, serves to guide normal tissue renewal, maturation and thereby restore healing.



Contact Info

Tissue Therapies Limited

L19
179 Turbot Street
Brisbane, QLD
AU Australia, 4000

Phone: +61 7 3334 3900
Fax: +61 7 3334 3999
Website: http://www.tissuetherapies.com

Click here to view the interactive map
Tissue Therapies Limited Google Map
Tissue Therapies Limited Google Map

Share Registry

Link Market Services Limited - Click here to view share registry profile

Phone: +61 2 8280 7100
Fax: N/A
Email: info@linkmarketservices.com.au
Website: http://www.linkmarketservices.com.au/

Level 12
680 George Street
Sydney, NSW
AU Australia, 2000


Important Information

The General Overview, Services, Products and Projects information for this profile was last edited on 18 Mar 2015.

All Financial Data is provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Share Prices nor any independent data provider is liable for any informational errors, omissions or other defects, incompleteness, or delays, or for any actions taken in reliance on Financial Data.

Please read our Terms & Conditions and Disclaimer Statement for further information.

Home

Search

Login

Report a bug